抄録
The survival period and effect of chemotherapy of 46 cases with T-cell malignant lymphomas (T-ML) which included many cases with adult T-cell lymphoma were analyzed.
The results were as follows;
1) Fifty percent survival of 46 cases with T-ML from the start of chemotherapy was 10 months. Statistical analysis revealed that the prognosis of the patients was not correlated with histologic subtypes according to the LSG criteria, but adversely with the levels of serum LDH before chemotherapy (p<0.05).
2) Those cases who achieved complete remission, whose LDH levels (LDH≥600 U before chemotherapy) decreased to less than 300 U (normal range; 202∼435 U) by 2 months after start of chemotherapy, in whom Adriamycin (ADM) of more than 40 mg weekly was given at least over 2 weeks in VEPA therapy, and in whom total administration doses of ADM were more than 180 mg by 2 months after the start of chemotherapy, survived significantly longer than the patients who did not achieve above-mentioned items. Administration of ADM more than 40 mg weekly at least over the periods of 2 weeks in VEPA therapy, decrease of serum LDH level to less than 300 U (target point), and total administration doses of ADM more than 180 mg during the period of induction chemotherapy of T-ML, were proposed as strategy to improve the complete remission rate and survival of T-ML.
